embryo
• in spiral artery walls at gestational day 12.5 and 18.5
• significant expansion of trophoblasts in labyrinth and junctional zone of placentas, leading to an overall increase in labyrinth, junctional zone and overall placenta depth at gestational day 18.5
• discontinuous trophoblast invasion of decidua basalis with select areas showing deep invasion reaching uterine wall at gestational day 18.5
|
• ~70% reduction in CD45+, CD122+ CD3-, DBA- NK1.1+ NK cell frequency at gestational day 8.5
• reduction in tissue resident NK (trNK) cells at implantation sites at gestation day 8.5
• normal ILC1 and conventional NK (cNK) cell numbers at implantation sites at gestational day 8.5
|
endocrine/exocrine glands
• ~70% reduction in CD45+, CD122+ CD3-, DBA- NK1.1+ NK cell frequency at gestational day 8.5
• reduction in tissue resident NK (trNK) cells at implantation sites at gestation day 8.5
• normal ILC1 and conventional NK (cNK) cell numbers at implantation sites at gestational day 8.5
|
hematopoietic system
• ~70% reduction in CD45+, CD122+ CD3-, DBA- NK1.1+ NK cell frequency at gestational day 8.5
• reduction in tissue resident NK (trNK) cells at implantation sites at gestation day 8.5
• normal ILC1 and conventional NK (cNK) cell numbers at implantation sites at gestational day 8.5
|
• reduced Ly49G2+ NK cell frequency
|
• impaired IL-2 and IL-15 induced priming and proliferation
|
• impaired ability to clear injected melanoma tumor cells (higher tumor burden)
• impaired ability to clear beta2M-deficient splenocytes
|
immune system
N |
• normal frequency and development of B cells and CD8+ and CD4+ T cells
• normal NK cell frequency in spleen and bone marrow
• normal NK cell maturation and expression of activating (Ly49D, Ly49H) and inhibiting Ly49 receptors
|
• ~70% reduction in CD45+, CD122+ CD3-, DBA- NK1.1+ NK cell frequency at gestational day 8.5
• reduction in tissue resident NK (trNK) cells at implantation sites at gestation day 8.5
• normal ILC1 and conventional NK (cNK) cell numbers at implantation sites at gestational day 8.5
|
• reduced Ly49G2+ NK cell frequency
|
• impaired IL-2 and IL-15 induced priming and proliferation
|
• impaired ability to clear injected melanoma tumor cells (higher tumor burden)
• impaired ability to clear beta2M-deficient splenocytes
|
reproductive system
• reduction in tissue resident NK (trNK) cells at implantation sites at gestation day 8.5
• normal ILC1 and conventional NK (cNK) cell numbers at implantation sites at gestational day 8.5
• ~70% reduction in CD45+, CD122+ CD3-, DBA- NK1.1+ NK cell frequency at gestational day 8.5
|
mortality/aging
N |
• viable
|